Hiroshi Tanaka

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang et al. · Nature Communications · 2019 · 351 citations · Full text

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

Shunichi Sugawara, J.-S. Lee, Jin‐Hyoung Kang et al. · Annals of Oncology · 2021 · 192 citations · Full text

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

Kōichi Goto, Yuichiro Ohe, Taro Shibata et al. · The Lancet Oncology · 2016 · 147 citations

Second-line Treatment, Medicine, Randomised Phase 3 +9

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 123 citations · Full text

<i>MUC12</i> mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer

Takatoshi Matsuyama, Toshiaki Ishikawa, Kaoru Mogushi et al. · International Journal of Cancer · 2010 · 117 citations · Full text

Radiation Oncology, Oncology, Stage Ii +15